ATE429233T1 - Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten - Google Patents

Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Info

Publication number
ATE429233T1
ATE429233T1 AT02751212T AT02751212T ATE429233T1 AT E429233 T1 ATE429233 T1 AT E429233T1 AT 02751212 T AT02751212 T AT 02751212T AT 02751212 T AT02751212 T AT 02751212T AT E429233 T1 ATE429233 T1 AT E429233T1
Authority
AT
Austria
Prior art keywords
glycoinhibitor
infectious diseases
against infectious
substance against
neutral glycan
Prior art date
Application number
AT02751212T
Other languages
English (en)
Inventor
Jari Natunen
Halina Miller-Podraza
Susann Teneberg
Jonas Angstroem
Karl-Anders Karlsson
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011402A external-priority patent/FI20011402A7/fi
Priority claimed from FI20011403A external-priority patent/FI20011403A7/fi
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Application granted granted Critical
Publication of ATE429233T1 publication Critical patent/ATE429233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02751212T 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten ATE429233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011402A FI20011402A7 (fi) 2001-06-29 2001-06-29 Lääkkeet ja hoitotavat patogeenejä vastaan
FI20011403A FI20011403A7 (fi) 2001-06-29 2001-06-29 Menetelmä ja koostumukset vatsan sairauksien hoitoon
PCT/FI2002/000574 WO2003002127A1 (en) 2001-06-29 2002-06-28 Use of at least one glycoinhibitor substance

Publications (1)

Publication Number Publication Date
ATE429233T1 true ATE429233T1 (de) 2009-05-15

Family

ID=26161191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751212T ATE429233T1 (de) 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Country Status (7)

Country Link
US (1) US20040176320A1 (de)
EP (1) EP1411952B1 (de)
JP (1) JP2005504017A (de)
AT (1) ATE429233T1 (de)
AU (1) AU2002352531A1 (de)
DE (1) DE60232077D1 (de)
WO (1) WO2003002127A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411962B1 (de) 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
EP1531832B1 (de) * 2002-06-28 2009-04-15 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
PT1675601E (pt) † 2003-10-13 2009-08-31 Nestec Sa Moderação do efeito de endotoxinas
US20070074300A1 (en) * 2005-09-28 2007-03-29 Suleiman Igdoura Sialidase inhibitors for the treatment of cardiovascular disease
JP5035787B2 (ja) * 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
EP2484696B1 (de) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
EP2060257A1 (de) * 2007-11-08 2009-05-20 Nestec S.A. Vorbeugung und Behandlung von Sekundärinfektionen nach Virusinfektion
EP2265135B1 (de) 2008-03-14 2017-12-20 Nestec S.A. Synbiotische mischung
US9301540B2 (en) * 2008-06-09 2016-04-05 Georgia-Pacific Panel Products Llc Prebiotic composition and methods of making and using the same
GB0817908D0 (en) * 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
US9678005B1 (en) * 2008-12-03 2017-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms
US8785402B2 (en) * 2009-07-31 2014-07-22 Academia Sinica Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions
US8828970B2 (en) 2009-08-27 2014-09-09 Georgia-Pacific Wood Products Llc Methods of making and using a ruminant gas reduction composition
WO2011072051A2 (en) 2009-12-08 2011-06-16 Temple-Inland Nutritional composition and methods of making and using same
WO2011094536A1 (en) * 2010-01-28 2011-08-04 Raptor Pharmaceuticalls Inc. Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates
US9226517B2 (en) 2010-03-25 2016-01-05 Taihua Shouyue (Hong Kong) International Co Limited Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells
US20180195035A1 (en) * 2014-02-12 2018-07-12 Goddard Labs, Inc. Rapid Detection of Human Pathogens in Plant Material Or Water
KR20160132034A (ko) 2014-03-13 2016-11-16 우니페르시테트 바젤 미엘린-관련 당단백질에 대한 IgM 항체와 결합하는 탄수화물 리간드
KR101613964B1 (ko) 2014-05-20 2016-04-21 농업회사법인 주식회사 생명의나무 글라이코매크로펩타이드 효소분해물을 유효성분으로 하는 헬리코박터 파이로리 감염 예방 또는 치료용 조성물
HK1252262A1 (zh) 2015-09-16 2019-05-24 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
EP3184536A1 (de) * 2015-12-22 2017-06-28 Westfälische Wilhelms-Universität Münster Oligosaccharidzusammensetzung zum binden an lectine
WO2017109587A1 (en) * 2015-12-22 2017-06-29 Universidad Nacional De Colombia "glycoinhibitors of adherence" of streptococcus in fish
JP2021528406A (ja) * 2018-06-19 2021-10-21 グリコス バイオメディカル オーワイ コンジュゲート

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
CN1121311A (zh) * 1993-02-26 1996-04-24 扬·施塔芬·诺马克 应用低聚糖苷作为细菌粘连的抑制剂
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5641760A (en) * 1994-06-17 1997-06-24 Pence, Inc. Method of treating candida infection
EP0918526A1 (de) * 1996-05-03 1999-06-02 Neose Technologies, Inc. Bismuthsalz von sialyloligosaccharid und verfahren zur behandlung von magen- und duodenalgeschwürer damit
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof

Also Published As

Publication number Publication date
DE60232077D1 (de) 2009-06-04
US20040176320A1 (en) 2004-09-09
EP1411952A1 (de) 2004-04-28
EP1411952B1 (de) 2009-04-22
JP2005504017A (ja) 2005-02-10
WO2003002127A1 (en) 2003-01-09
AU2002352531A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
ATE429233T1 (de) Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
PT1333887E (pt) Metodo de tratamento de desordens musculares
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0408295A (pt) uso de um composto
DK1368019T3 (da) Esmololformulering
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60128100D1 (de) Analgetisches arzneimittel
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
SE0004101D0 (sv) New use
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
HRP20050611B1 (hr) Kombinacijski lijek
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties